...While Drug Importers Forecast High Growth

1 September 1996

German drug import companies are forecasting high growth this year, though an arbitration committee in the capital, Bonn, has still to decide whether pharmacies are obliged to supply re-imports of German drugs which are 10%-35% cheaper in neighboring countries.

Andreas Mohringer, executive director of one of Germany's leading importers Eurim Pharma, who also runs a pharmacy business in the Ruhr, says there are opportunities in re-imports for pharmacies and patients, as well as import companies, and an opportunity to reduce German drug costs. Mr Mohringer has just returned from a visit to the UK where, he said, he could buy a German-made cough medicine more cheaply than he has to pay to stock it in his pharmacy.

Eurim reported sales of 54 million Deutschemarks ($36.3 million) in 1995, selling 600 products and rapid diagnostic tests, and expects 1996 sales to rise to 60 million marks. 90% of the product range consists of re-imported items which are "Germanized" at the company's base, with new patient package inserts and logos, and product retesting.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight